Salta al contenuto principale
Passa alla visualizzazione normale.

MARIA ROSARIA VALERIO

Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies

  • Autori: Cazzaniga M.E.; Verusio C.; Ciccarese M.; Fumagalli A.; Sartori D.; Valerio M.R.; Airoldi M.; Moretti G.; Ficorella C.; Gianni L.; Michelotti A.; Zambelli A.; Febbraro A.; Generali D.; Pistelli M.; Garrone O.; Musolino A.; Vici P.; Maur M.; Mentuccia L.; La Verde N.; Bianchi G.V.; Artale S.; Blasi L.; De Laurentiis M.; Atzori F.; Turletti A.; Porpiglia M.; Santini D.; Fabi A.; Gebbia V.; Schirone A.; Palumbo R.; Ferzi A.; Frassoldati A.; Scavelli C.; Clivio L.; Giordano M.; Donadio M.; Biganzoli L.; Del Mastro L.; Bisagni G.; Livi L.; Natoli C.; Montemurro F.; Riccardi F.; Romagnoli E.; Marchetti P.; Torri V.; Pronzato P.; Mustacchi G.
  • Anno di pubblicazione: 2019
  • Tipologia: Articolo in rivista (Articolo in rivista)
  • OA Link: http://hdl.handle.net/10447/359852

Abstract

Background: Different studies suggest that fulvestrant 500 mg every 28 days (HD-FUL) could be an active treatment in HR+ advanced breast cancer (ABC) patients even treated with aromatase inhibitors in the adjuvant setting. The aim of this analysis is to describe the outcome of ABC patients treated with HD-FUL as first-line treatment in terms of median duration of treatment and the overall response rate in a real-world setting. Methods: For the purpose of the present analysis, we considered two data sets of HR+ ABC patients collected in Italy between 2012 and 2015 (EVA and GIM-13 AMBRA studies). Results: Eighty-one and 91 patients have been identified from the two data sets. The median age was 63 years (range 35-82) for the EVA and 57.8 years (range 35.0-82.3) for the AMBRA patients. ORRs were 23.5 and 24.3% in the whole population, 26.9% in the patients with bone only, and 21.8 and 21.4% in those with visceral metastases. The median duration of HD-FUL was 11.6 months (range 1-48) and 12.4 months (range 2.9-70.0) in the two data sets, respectively. Conclusion: These data suggest that HD-FUL should still continue to play a significant role as first-line therapy in HR+ ABC patients.